This project focuses on immunoprevention of pancreatic adenocarcinoma rather than treatment of existing disease. The advantage of having a model to study the development of premalignant lesions is that we can investigate therapies to halt neoplastic progression. Prophylactic vaccines directed against tumor antigens may be one of the most effective prevention approaches under consideration. Vaccines have been used for centuries to help improve host immune responses against infectious pathogens. Boosting a patient's native immune responses against malignancy will provide a life-long tumor surveillance similar to life-long surveillance against infectious diseases preventable by vaccination. Cancer vaccines, particularly those using dendritic cells to deliver the antigen of choice in immunologic context, are showing promising results in controlling cancer. Our proposal to develop a preventive pancreatic cancer vaccine in a spontaneous model of Pan IN lesions is novel and it will provide further support for the possibility of treating patients early before their lesions progress to established tumors. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32CA119780-01
Application #
7052522
Study Section
Special Emphasis Panel (ZRG1-F09 (20))
Program Officer
Lohrey, Nancy
Project Start
2006-05-05
Project End
2008-05-04
Budget Start
2006-05-05
Budget End
2007-05-04
Support Year
1
Fiscal Year
2006
Total Cost
$52,048
Indirect Cost
Name
University of Pittsburgh
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Finn, Olivera J; Gantt, Kira R; Lepisto, Andrew J et al. (2011) Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol Res 50:261-8